Efficiency of SARS-CoV-2 vaccines in breast cancer patients: single institutional experience from Institute for Oncology and Radiology of Serbia (IORS)
Annals of Oncology
; 33(Suppl. 3):S230-S230, 2022.
Artigo
em Inglês
| GIM | ID: covidwho-2035757
ABSTRACT
Background:
Cancer patients are more sensitive to infection induced by SARS-CoV-2, especially ones with impaired immune response. Vaccines are approved as safe and effective, and they are recommended in oncology patients. The aim of our study was to see the percentage of reinfections after second dose of vaccines against SARS-CoV2.
human diseases; coronavirus disease 2019; viral diseases; pandemics; public health; efficacy; vaccines; vaccination; immunization; health protection; disease prevention; breast cancer; breast; neoplasms; immunocompromised hosts; patients; epidemiology; immune response; safety; dosage; reinfection; metastasis; drug therapy; risk reduction; pneumonia; lungs; respiratory diseases; mortality; disease course; immune sensitization; man; Severe acute respiratory syndrome coronavirus 2; Serbia; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Balkans; Southern Europe; Europe; Mediterranean Region; upper-middle income countries; very high Human Development Index countries; SARS-CoV-2; viral infections; mammary tumour; cancers; breasts; Srbija; immunity reactions; immunological reactions; chemotherapy; lung diseases; death rate; disease progression
Texto completo:
Disponível
Coleções:
Bases de dados de organismos internacionais
Base de dados:
GIM
Tópicos:
Vacinas
Idioma:
Inglês
Revista:
Annals of Oncology
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS